Prime Medicine (NYSE:PRME) Upgraded by StockNews.com to “Sell”

StockNews.com upgraded shares of Prime Medicine (NYSE:PRME – Free Report) to a sell rating in a report published on Wednesday. Several other brokerages also recently commented on PRME. HC Wainwright began coverage on Prime Medicine in a research note on Monday, May 20th. They set a buy rating and a $10.00 target price on the […]

Leave a Reply

Your email address will not be published.

Previous post Dutch Bros Inc. (NYSE:BROS) Receives $39.55 Consensus Target Price from Analysts
Next post Knight-Swift Transportation (NYSE:KNX) Cut to “Peer Perform” at Wolfe Research